Who Gets Counted in Menopause Knowledge
The menopause information environment is shaped not only by what people search for, but also by whose experience researchers have measured. This discussion examines the 84 primary studies in a global scoping review of menopause symptom awareness: how the studies were selected, where they were conducted, who participated, and which symptoms they named. The practical judgment is simple but demanding: before treating an awareness finding as a global truth, ask who was studied, where, with what method, and about what kind of experience.
What an evidence map can—and cannot—tell us
A scoping review is designed to map a field. It can show the types of research that exist, the populations and places represented, and recurring gaps in the questions researchers ask. It is different from a single survey that estimates awareness in one defined population, and it is not a census of every person’s knowledge. That distinction matters because a large search yield can create an impression of comprehensiveness long before the evidence is actually representative.
The review searched Ovid MEDLINE, PubMed, and Web of Science for eligible primary research through June 2025. The databases returned 17,577 records. After 8,126 duplicates were removed and the remaining records were screened, 9,367 were excluded for failing to meet the eligibility criteria. The final sample contained 84 primary studies published between 1980 and 2025. The review included original qualitative and quantitative research into menopause or symptom awareness, while excluding, among other categories, studies focused solely on health-care practitioners’ awareness, reviews, protocols, and research without an English translation.
The final number is therefore meaningful, but only within its method. It tells us how many studies met this review’s stated criteria; it does not tell us how many relevant studies exist in every language, database, or community. The 84 studies also differed substantially in design. Sixty-five used quantitative approaches, 14 used qualitative approaches, and 5 used mixed methods. Sample sizes ranged from 15 to 2,509. A questionnaire administered to a large defined group and an in-depth qualitative study with 15 participants may answer different questions about awareness. Neither automatically outranks the other; each makes a different kind of knowledge visible.
The review’s process is summarized below:
The diagram’s last box is as important as the count. A review can be systematic and still inherit the blind spots of the literature it finds. It can also lose relevant work through language restrictions or database coverage. The authors excluded papers that were not available in English or with an English translation, partly because they were concerned that automated translation could lose culturally important nuance. They also note that relevant studies may have been missed despite using broad databases.
This is not a reason to disregard the review. It is a reason to interpret it as a map of available evidence rather than a final measurement of global awareness. A map is useful precisely because it shows both the roads and the blank spaces.
Where the map is dense—and where it is thin
The geographic pattern is uneven. Most of the reviewed research was conducted in Asian countries, notably Iran, India, and Pakistan, and in North America, particularly the United States. Africa contributed seven studies, 8.3% of the final sample, and those studies sampled six countries. Oceania was the least researched continent: two studies sampled populations from Australia, while none focused on Pacific Island communities. The review also found a strong bias toward studies in higher-income countries compared with lower-income regions.
These figures describe research coverage, not a league table of people’s knowledge. Seven African studies do not mean that African populations have one shared awareness level, just as a large number of studies in Asia does not make Asian experience uniform. The number of studies, the countries included, the populations recruited, and the tools used to measure awareness all affect what a regional comparison can mean. The review explicitly cautions that the unequal number of studies limits comparison.
The gap matters because awareness campaigns are applied in places, not in an abstract global average. Cultural expectations, languages, access to education and health services, patterns of work and caregiving, and common sources of support can all affect whether a message is recognized as relevant. If a campaign is designed mainly from evidence collected in high-income or English-speaking settings, it may still contain accurate facts while failing to answer the questions that matter in another setting. The problem is not necessarily that the facts are false. It is that the pathway from information to use has not been tested for the people being addressed.
The review suggests possible reasons for the concentration in wealthier settings, including health priorities, funding, and access to menopause education and training. Those are plausible contributors, not quantified causes established by the review. Keeping that distinction visible prevents an evidence gap from becoming a story about the supposed lack of interest or capacity in an underrepresented community. Missing research may reflect institutional resources, publication systems, language barriers, or the priorities of researchers and funders rather than the priorities of the people whose experiences remain unmeasured.
The same caution applies to the global North and global South as broad labels. Regions contain different health systems, cultures, income groups, and menopause experiences. The value of the geographic map is not to rank them. It is to show that the evidence base is too concentrated to support a universal account without qualification, and that the missing work has practical consequences for tailoring public information.
Who is missing from the picture
The review’s population profile is also narrower than the social world in which menopause is experienced. Seventy-two of the 84 studies used women-only samples. Men appeared in 12 studies: six all-male studies and six mixed-gender studies. Only one study included non-binary participants. Most of the women’s studies focused on people who were already menopausal, while younger adults and people before menopause were less consistently represented.
That pattern is understandable if the immediate research question is how people experiencing menopause recognize symptoms. It is insufficient if the question is how a society becomes capable of supporting them. A partner may influence whether a symptom can be discussed at home. A colleague or manager may shape whether sleep disruption or concentration problems are treated as a health issue or as a performance failure. A younger person may need knowledge before a parent or relative begins the transition. A health professional needs to understand the concerns a patient brings from family, work, community, or the internet.
The review argues that education should reach people within social and professional networks, not only those currently going through menopause. That is a claim about the audience that awareness efforts need to serve, not proof that every member of a network will respond in the same way. It also does not mean assigning one support role to a particular gender or relationship. The review notes that the typical source of support differs across countries and may include female family members, husbands, blood relatives, or friends. A campaign that assumes one universal household or support structure can miss the route by which information becomes usable.
Gender diversity is an especially important boundary. The review reports that transgender people were not explicitly included in the identified studies and that gender diversity was reported in only one study. This should be read as a statement about the reviewed research, not evidence that transgender or gender-diverse people lack menopause experiences or that their needs are uniform. Previous hormone use, gender identity, and the clinical and social settings in which someone seeks information may create questions that a women-only survey does not capture. The review calls for targeted awareness work to be developed with the communities concerned.
The denominator changes the meaning of a claim. “Most studies found…” can sound broad while describing a sample that excludes the people who provide support, the people who encounter menopause indirectly, or the people whose identities do not fit the dominant sample. A more careful question is: most studies found what, among whom, under which definition of menopause and awareness? That extra detail is not bureaucratic decoration. It determines whether a result can travel from one setting to another.
What gets named as a symptom
Representation is not only about people and countries. It is also about the body and the experiences that a study chooses to ask about. Only 47 of the 84 reviewed papers explicitly mentioned specific symptom domains, about 56% of the final sample. Among those papers, physical symptoms were most frequently mentioned, appearing in 43 studies. Vasomotor and psychosocial symptoms each appeared in 39, and sexual symptoms in 31. Ocular symptoms were explicitly assessed in only four studies, 4.8% of the full sample.
These counts do not tell us which symptoms are most common or most serious. They tell us which symptoms received explicit attention in the reviewed research. That is still important, because what is repeatedly named is more likely to enter education, questionnaires, conversations, and search vocabulary. What is rarely named can remain difficult to recognize even when it affects daily life.
Ocular symptoms make the distinction visible. The review notes that dry eye, vision changes, and light sensitivity are common when specifically investigated, yet they are rarely included in general surveys of menopause knowledge. It reports a cited prevalence of roughly 60% to 80% for dry eye in perimenopause, but that estimate comes from other studies cited by the review, not from the scoping review’s own 84-study sample. The review also says that the few studies examining ocular symptoms found low awareness compared with more familiar domains.
The implication is not that every eye symptom should be attributed to menopause. Frequency of mention is not clinical prevalence, and a symptom can have more than one possible cause. The implication is that an awareness measure can look reasonably complete while omitting an entire domain of experience. If the question does not name an experience, a respondent cannot demonstrate awareness of it through that instrument. The silence may belong to the questionnaire rather than to the population.
This is why an exhaustive symptom list would not solve the problem. A long list can overwhelm readers and encourage self-diagnosis, while a short list can conceal important variation. A better measure explains what it includes, what it leaves out, and why the selected domains are relevant to the people being studied. It treats symptom coverage as part of the evidence design.
Awareness scores are signals, not league tables
To compare findings across studies, the review coded reported awareness on a numerical scale from 0 to 5, ranging from unclear to high. After studies with unclear levels were excluded, the global average was 2.3, with a standard deviation of 1.0. None of the studies was graded as showing high menopause symptom awareness. That pattern supports a broad conclusion that incomplete awareness is common in the reviewed literature.
The review also reports different coded means by continent: 1.9 in North America across 12 studies, 2.0 in Oceania across 2, 2.1 in Africa across 7, 2.2 in Asia across 42, 2.3 in Europe across 14, and 3.1 in South America across 7. By reported gender composition, mixed men-and-women samples had a mean of 3.2 across 5 studies, all-women samples 2.2 across 71, and all-men samples 2.0 across 7.
Those numbers invite ranking, but the review warns against that use. The underlying studies used different scales and methods, and the number of studies in each group was highly unequal. Qualitative studies were more likely to receive an unclear code because rich, contextual accounts are difficult to translate into one numerical score. A mean based on two studies does not carry the same evidentiary weight as a mean based on 42, and a higher coded average in one group does not show that group composition caused greater awareness.
The scores are therefore signals about the state of the literature, not precise measurements of human worth or fixed regional ability. They tell us that high awareness was not documented in any included study under the review’s coding approach, while also telling us that cross-study comparison remains approximate. New research with common definitions, standardized testing, broader representation, and more direct cross-cultural comparisons could change the precision of that conclusion. It might raise, lower, or redistribute the observed averages; more importantly, it could show which differences persist after method and population are made more comparable.
That is the practical lesson of the evidence map. A trustworthy claim about menopause awareness carries its denominator, its setting, its symptom scope, and its design. It distinguishes an absence of measured evidence from evidence that an experience does not exist. It treats an underrepresented region as a reason to investigate and tailor, not as an empty space to fill with assumptions.
The result is a more demanding picture of the menopause information environment. Public attention can expand, but the knowledge available to interpret that attention remains shaped by who was invited into research, what questions were asked, and which symptoms were considered visible. Once those limits are in view, search trends can be read as evidence about attention without being asked to stand in for understanding itself.